But the drug industry said that the move would backfire, with the Pharmaceutical Research and Manufacturers of America predicting that allowing more manufacturers to begin making shots would spark new competition for limited ingredients, slow down existing production and even lead to counterfeit vaccines. “If the end goal is to help other countries vaccinate their people, this is more political theater than it is substance,” said Brent Saunders, a longtime biotech CEO who now leads Vesper Healthcare Acquisition Corp., saying it could take years to build new factories to produce coronavirus vaccines. “If the government wanted to be helpful, it would help expand the manufacturing capacity of the existing companies.” Administration officials have acknowledged their uncertainty about whether the waiver will actually speed up production of coronavirus vaccines across the world. The mRNA vaccines, made by Pfizer-BioNTech and Moderna, require special technology that most countries do not have access to, raising questions about which countries will actually have the technological capacity to manufacture the complicated vaccines.